pp-010 Capsules 50 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Comments
Orally active PARP-1/2 inhibitor, Approved indications: Germline BRCA1/2–mutated, platinum-sensitive recurrent ovarian cancer, Fallopian tube cancer, Primary peritoneal cancer. Ovarian Cancer - Phase Ib & III trials; Breast Cancer -Phase III;
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days